Authorities in US sue Novartis in kickback scheme

by Jake Pearson

Novartis Pharmaceuticals Corp. paid kickbacks to a specialty pharmacy in exchange for recommending refills of a blood transfusion drug it produces, according to an amended complaint filed Wednesday in a civil case brought by state and federal prosecutors in New York.

The East Hanover, New Jersey-based company boosted its sales of the iron-reduction drug Exjade by giving referrals and rebates to pharmacy BioScrip, which recommended refills to its but often ignored warning them of the drug's potentially fatal side effects, which include kidney failure and gastrointestinal hemorrhaging, according to the complaint filed in Manhattan federal court.

BioScrip, based in Elmsford, New York, agreed to pay $15 million to settle charges that it caused pharmacies to submit tens of thousands of false claims to Medicare and Medicaid, New York Attorney General Eric T. Scheniderman said.

"This arrangement between Novartis and BioScrip was dangerous for patients and is against the law," he said in a statement. "Our lawsuit against Novartis and our agreement with BioScrip send a clear message: Drug companies cannot pay pharmacies to promote drugs directly to patients."

In a statement, Novartis disputed the allegations and said it would defend itself against the litigation.

"At NPC, patients are the focus of all that we do," said company president Andre Wyss. "We want to support the best possible outcome for a patient taking a Novartis medication prescribed by their physician."

A spokesman for BioScrip didn't return a message seeking comment.

As part of its settlement with the government, BioScrip said that, beginning in 2007, Novartis told the pharmacy its refills for Exjade patients were too low and that it would lose referrals if it didn't raise its numbers, according to court documents.

The pharmacy, using employees in an Ohio call center, encouraged patients—some who had stopped using the drug—to refill their Exjade orders, according to the lawsuit.

The lawsuit seeks tens of millions of dollars in Medicare and Medicaid reimbursements.

Last April, sued Novartis, accusing it of using kickbacks disguised as rebates to turn 20 or more pharmacies into a sales force for its own drug, Myfortic, which is used for .

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

NY lawsuit accuses Novartis of health care fraud

Apr 24, 2013

The U.S. government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.

US sues Novartis in NY again, cites doc kickbacks

Apr 26, 2013

The U.S. government sued Novartis Pharmaceuticals Corp. again on Friday, saying it paid kickbacks for a decade to doctors to steer patients toward its drugs, sometimes disguising fishing trips off the Florida coast and trips ...

Feds fine St. Louis drug maker $3.5 million

Jul 19, 2013

(AP)—A St. Louis-based drug maker is paying $3.5 million to settle a federal lawsuit that it illegally paid doctors to prescribe out-of-date antidepressants and sleep aids to Medicare and Medicaid patients.

Japan to file criminal complaint against Novartis (Update)

Jan 07, 2014

Japan's health ministry plans to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, an official said Wednesday.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

23 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments